Tony Hitchcock | 05/24/2013
Throughout my career in the biotech industry I have been fortunate to work on a wide range of cutting edge projects to produce material for first in man studies, whether it be protein fragments, antibody conjugates, DNA, viral, whole cell bacterial vaccines as well as more “conventional” protein or antibody therapies. Throughout these projects , it has always been very apparent to me that the key factor as to why projects might succeed or fail is the people involved at all levels w...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 01 - 03, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More